Cytek Biosciences Inc at JPMorgan Healthcare Conference Transcript
Hello all and welcome. My name is Fawzi Kawash. I'm associate at JPMorgan. It's my pleasure to introduce Dr. Jiang of Cytek.
Good morning. Thanks to JPMorgan for inviting us to present you Cytek Biosciences. As usual, the Safe Harbor statement, I'm not going to read through.
So Cytek is a cell analysis company. We build our business based on our foundational four business pillars, which includes: instrument, applications, bioinformatics, and clinical. I'm going to get into details of all those points in the following presentation.
To start with, I'm going to give you a summary of our performance. Cytek, in 2016, we launched our first product, Athena, which is a conventional flow cytometer. A year later, we launched Cytek Aurora, our flagship product based on the full spectral flow technology, which is a cell analyzer. And a year later, we launched the Northern Lights, which helped to serve the entry-level applications in the cell analysis.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |